Saltar al contenido
Merck

A novel regulatory circuit of miR‑152 and DNMT1 in human bladder cancer.

Oncology reports (2018-07-18)
Haiqing Zhang, Defeng Qi, Jinhui Li, Tao Peng, Linqing Yang, Jianhui Yuan, Yuying Zhang, Yuan Hu, Jialin Su, Biao Que, Mengxi Li, Guoren Zhou, Yuxin Chen, Wenjuan Zhang, Weidong Ji
RESUMEN

Downregulation of microRNA‑152 (miR‑152) has been observed in various types of human malignancies, including Bladder cancer (BC). However, the role of miR‑152 in the development and progression of BC is still unclear. In our previous study, we identified a functional crosstalk between miR‑152 and DNA methyltransferase 1 (DNMT1) involved in Nis‑induced malignant transformation. In the present study, we found that the expression of miR‑152 was specifically downregulated in BC cells and tissues via the DNA hypermethylation of the miR‑152 promoter. The overexpression of miR‑152 in BC cells resulted in a reduction of DNMT1, whereas the inhibition of the expression of miR‑152 induced an elevated level of DNMT1. Further studies revealed that miR‑152 directly downregulated the expression of DNMT1 by targeting the 3'‑UTR of its transcript in BC cells. In addition, ectopic expression of miR‑152 in BC cells significantly inhibited cell proliferation, whereas the inhibition of miR‑152 expression led to increased cell proliferation. These findings indicated a novel regulatory circuit of miR‑152/DNMT1 in BC, and more importantly, the combination of miR‑152 and DNMT1 may function as promising therapeutic modalities and early biomarkers for BC.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-DNMT1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution